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Background: Healthy life expectancy (HLE) is used as one of the primary objectives of fundamental
health promotion plans and social development plans. Activity limitation is used to calculate HLE, but
little study has been done to identify determinants of activity limitation in order to extend HLE. The
purpose of this study is to identify diseases and injuries that commonly lead to activity limitation to
prioritize countermeasures against activity limitation.
Methods: We used anonymous data from the 2007 “Comprehensive Survey of Living Conditions,”
collected by the Ministry of Health, Labour and Welfare of Japan according to the Statistics Act, Article 36.
We used logistic regression analyses and calculated odds ratios (ORs) after adjusting for age and sex.
Limitation in daily activities was applied as the dependent variable, and each disease/injury was applied
as an independent variable in this analysis. Furthermore, population attributable fractions (PAFs) were
calculated.
Results: The provided data included 98,789 subjects. We used data for 75,986 valid subjects aged 12
years or older. The following diseases showed high PAF: backache (PAF 13.27%, OR 3.88), arthropathia
(PAF 7.61%, OR 4.82), eye and optical diseases (PAF 6.39%, OR 2.01), and depression and other mental
diseases (PAF 5.70%, OR 11.55). PAFs of cerebrovascular diseases, hypertension, and diabetes were higher
for males than for females; on the other hand, PAFs of orthopedic diseases were higher among females.
Conclusions: Our results indicate that orthopedic diseases, ophthalmic diseases, and psychiatric diseases
particularly affect activity limitation.
© 2016 The Authors. Publishing services by Elsevier B.V. on behalf of The Japan Epidemiological
Association. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
licenses/by-nc-nd/4.0/).1. Introduction
Healthy life expectancy (HLE) is used as one of the primary
objectives of fundamental health promotion plans1e4 and social
development plans. Japan has adopted HLE as the ﬁrst objective of
the national health promotion plan, Health Japan 21 (the second
term), which was launched in 2012, and also uses HLE as a domain
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d/4.0/).States used HLE as one of the main target objectives for Healthy
People 2010 and Healthy People 2020. The European Union (EU)
adoptedHealthy Life Years (HLY), which is the same as HLE, in social
development plans, such as the Lisbon Strategy and Europe 2020, in
addition to the health promotion plan of the EU health programme.
Health-adjusted life expectancy (HALE), which is a kind of HLE, is
also used to compare health status between countries.1,5e7 Pro-
longing HLE is important for health policy in each country and
region. Several studies have investigated the risk factors of reduced
HLE and reported effects of educational disparities, socioeconomic
status, and chronic diseases.8e10 Hashimoto11 reported that elimi-
nation of diseases and injuries in Japan increased HLE.
There are several indices for HLE, such as life expectancy
without activity limitation, good perceived health, absence of
chronic morbidity, and the average period of time spentn Epidemiological Association. This is an open access article under the CC BY-NC-ND
Table 1
Age-class distribution of the proportion of activity limitation by gender and age
class.
Male Female
n % n %
12e14 1385 5.85 1269 4.41
15e19 2424 5.53 2137 4.49
20e24 2195 3.87 2154 5.80
25e29 2382 5.00 2433 5.88
30e34 3069 5.05 3254 6.45
35e39 3219 5.90 3435 7.57
40e44 2778 6.44 2915 7.99
45e49 2750 6.84 2848 10.22
50e54 2921 8.87 2962 11.88
55e59 3626 11.20 3702 12.51
60e64 2810 13.67 2822 13.43
65e69 2506 17.16 2638 18.61
70e74 2049 23.47 2363 23.83
75e79 1473 28.65 1811 34.07
80e84 818 39.00 1342 42.77
85e89 325 43.08 689 54.28
90- 139 48.20 343 60.93
Total 36,869 10.96 39,117 13.90
% is the proportion of subjects with activity limitation divided by all subjects of the
age class.
T. Myojin et al. / Journal of Epidemiology 27 (2017) 75e7976independently in daily activities. Among them, the most popular
index is life expectancy without activity limitation, calculated by
the Sullivan method12 using mortality rates and proportion of ac-
tivity limitation for each age group. Therefore, revealing de-
terminants of activity limitation is useful for prolonging HLE, aside
from determinants of mortality. WHO13 deﬁnes activity limitation
as difﬁculty encountered by an individual in executing tasks or
actions in everyday life. Difﬁculties in activities of daily living (ADL)
correspond to the most severe level of activity limitation.14 Many
studies15e17 have examined the risk factors of impairment of ADL.
However, activity limitation, which is used to calculate HLE, is less
serious than ADL impairment, and the risk factors of the two might
be different. It is important to identify determinants of activity
limitation in order to extend HLE.
The purpose of this study is to identify diseases and injuries




We used data of activity limitation and diseases and injuries for
treatment from the 2007 Comprehensive Survey of Living Condi-
tions,18 which is a self-administered questionnaire survey for all
residents living in 5440 areas selected by stratiﬁed random sam-
pling method of census enumeration districts in Japan.19,20 This
survey is conducted every 3 years. The response rate of the 2007
survey was 79.9%. Data were provided by the Ministry of Health,
Labour and Welfare, Japan with permission according to the Sta-
tistics Act, Article 36. These data were resampled to make the
original data anonymous. The 2007 data is the latest of the pro-
vided information.
Activity limitation in this surveywas evaluated using the answer
to the question “Is your daily life now affected by health problems?”
A respondent who answered “Yes” was considered to have an ac-
tivity limitation. On the other hand, a respondent who answered
“No” was considered to be without activity limitation.
Diseases and injuries requiring treatment were evaluated by
answers to the following two questions: “Do you now go to a
hospital, clinic, or a facility for Japanese traditional massage,
acupuncture, moxibustion, or judo-orthopedics for diseases or in-
juries?” and “What are your diseases or injuries?” The second
question was multiple choice with questions regarding 39 diseases
or injuries, and was asked of persons who replied “Yes” to the ﬁrst
question.
2.2. Statistical analyses
Odds ratios (ORs) of activity limitation for both sexes, and for
males and females separately, were computed from logistic
regression analyses adjusted for age group and sex (for both sexes).
Being with or without activity limitation was assigned as a
dependent variable. Each disease and injury for treatment was
assigned as an independent variable for respective models. Ana-
lyses were performed with SPSS ver.21 for Windows (IBM, New
York, NY, USA).
In addition, we computed population attributable fractions
(PAF) for each disease and injury as follows:21
PAFX ¼ fðRRX  1Þ=RRXg*fAX=ðAX þ NAXÞg
where PAF refers to risk ratios (RRx), number of affected individuals
(Ax), and number of non-affected individuals (NAx). The affected
and non-affected individuals were among those having activitylimitation. We considered the RRs and ORs to be approximated
because the proportion with activity limitation was low among the
subjects. In this study, PAF means the proportion of people for
whom activity limitation would be expected to decrease if no
participant suffered from this disease or injury.3. Results
The provided data included 98,789 subjects. We used data for
75,986 subjects after eliminating 11,129 subjects who were less
than 12 years old, 10,573 subjects who had invalid responses to the
questions regarding activity limitation, and 1101 subjects w an
invalid response to the questions regarding each disease and injury
for treatment.
Table 1 shows the age-class distribution of the proportion of
those with activity limitations by gender. The proportion of par-
ticipants with activity limitation among old people was about 10
times higher than among young people. The proportion of partic-
ipants with activity limitation for males was higher than for fe-
males among those under 20 years old and was the reverse among
those over 20 years old.
Table 2 shows the number and proportion of outpatients with
each disease and injury among males and females, respectively. We
eliminated “infertility” from the analysis because its prevalence
was very low. Diseases with high prevalence for both sexes were
hypertension (9.88%), backache (5.25%), dental diseases (4.65%),
eye and optical diseases (4.40%), hyperlipemia (3.81%), and diabetes
(3.66%). These diseases were more prevalent among females than
males, except for diabetes.
Table 3 shows the OR and PAF for each disease and injury. For
both sexes, diseases and injuries showing high ORs were Parkin-
son's disease (19.27; 95% CI, 10.58e35.07), fracture (12.44; 95% CI,
9.91e15.63), depression and other mental diseases (11.55; 95% CI,
10.16e13.13), and other nervous diseases (9.37; 95% CI, 7.60e11.54).
The OR of Parkinson's disease was 29.47 (95% CI, 11.56e75.11) for
females and 13.15 (95% CI, 5.93e29.18) for males. In other words,
the OR for females was 2.2 times higher than for males.
Diseases and injuries showing high PAF for both sexes were
backache (13.27%), arthropathia (7.61%), eye and optical diseases
(6.39%), depression and other mental diseases (5.70%), and diabetes
Table 2
Number and prevalence of each disease and injury among both sexes and for males and females separately.
Both sexes Males Females
n % n % n %
01. Diabetes 2783 3.66 1681 4.56 1102 2.82
02. Adiposity 390 0.51 170 0.46 220 0.56
03. Hyperlipemia 2894 3.81 1202 3.26 1692 4.33
04. Thyroid diseases 697 0.92 137 0.37 560 1.43
05. Depression and other mental diseases 1096 1.44 433 1.17 663 1.69
06. Dementia 290 0.38 96 0.26 194 0.50
07. Parkinson's disease 98 0.13 41 0.11 57 0.15
08. Other nervous diseases 447 0.59 191 0.52 256 0.65
09. Eye and optical diseases 3344 4.40 1216 3.30 2128 5.44
10. Ear and aural diseases 717 0.94 296 0.80 421 1.08
11. Hypertension 7511 9.88 3576 9.70 3935 10.06
12. Cerebrovascular diseases 872 1.15 543 1.47 329 0.84
13. Angina pectoris and Myocardial infarction 1259 1.66 748 2.03 511 1.31
14. Other circulatory system diseases 1050 1.38 537 1.46 513 1.31
15. Acute rhinitis/laryngitis 367 0.48 135 0.37 232 0.59
16. Allergic rhinitis 1139 1.50 484 1.31 655 1.67
17. Asthma 796 1.05 358 0.97 438 1.12
18. Other respiratory system diseases 581 0.76 347 0.94 234 0.60
19. Gastric and duodenum diseases 1323 1.74 683 1.85 640 1.64
20. Hepatic and gallbladder disease 875 1.15 484 1.31 391 1.00
21. Other digestive system diseases 692 0.91 316 0.86 376 0.96
22. Dental diseases 3537 4.65 1552 4.21 1985 5.07
23. Atopic dermatitis 625 0.82 296 0.80 329 0.84
24. Other skin diseases 1465 1.93 663 1.80 802 2.05
25. Gout 600 0.79 553 1.50 47 0.12
26. Rheumatoid arthritis 505 0.66 110 0.30 395 1.01
27. Arthropathia 1686 2.22 464 1.26 1222 3.12
28. Stiff shoulder 2586 3.40 677 1.84 1909 4.88
29. Backache 3988 5.25 1566 4.25 2422 6.19
30. Osteoporosis 1000 1.32 61 0.17 939 2.40
31. Kidney diseases 587 0.77 310 0.84 277 0.71
32. Hypertrophy of prostate 801 1.05 801 2.17 e e
33. Failure at or after menopause 140 0.18 e e 140 0.36
34. Fracture 406 0.53 164 0.44 242 0.62
35. Injury or burn other than bone fracture 493 0.65 219 0.59 274 0.70
36. Anemia and Blood diseases 442 0.58 122 0.33 320 0.82
37. Malignant neoplasms 434 0.57 189 0.51 245 0.63
38. Pregnancy and Postpartum 177 0.23 e e 177 0.45
% is the percentage of affected individuals in the entire cohort among both sexes (N ¼ 75,986), males (N ¼ 36,869) and females (N ¼ 39,117).
T. Myojin et al. / Journal of Epidemiology 27 (2017) 75e79 77(4.99%). PAFs of cerebrovascular diseases, hypertension, diabetes,
angina pectoris, and myocardial infarction were higher for males
than for females. On the other hand, PAFs of osteoporosis, arthro-
pathia, stiff shoulder, backache, and rheumatoid arthritis were
higher for females than males. No diseases or injuries showed an
OR less than unity or a PAF less than zero.
4. Discussion
Our results showed that PAFs of orthopedic diseases,
ophthalmic diseases, and psychiatric diseases were high. Health
promotion strategies should prioritize these diseases in order to
prevent activity limitation. The PAF value depends on the propor-
tion of affected individuals and an OR for each disease and injury.
Even though the ORs of arthropathia, backache, and ophthalmic
diseases were not so high, PAFs were high because thereweremany
patients. On the other hand, fracture and neurological diseases
showed high ORs for activity limitation but lower PAFs (Table 3).
This is because the number of patients seen for fracture and
neurological diseases was small compared to those seen for
arthropathia, backache and ophthalmic diseases.
The Japanese Orthopedic Association mentions preventing
“Locomotive Syndrome” to extend HLE.22 Their paper was based on
data of causes of long-term care or support needs, which indicate
ADL impairment. In The Netherlands, it was reported that back pain
affected activity limitation.23 To our knowledge, however, ourpaper is the ﬁrst to show that orthopedic disease is the most
important disease affecting the more broadly deﬁned activity lim-
itation used to calculate HLE.
Past studies reported that ophthalmic disease decreased
quality-adjusted life-years (QALYs) in Singapore and also decreased
health-related quality of life in Korea.24,25 In addition, some studies
have estimated QALY loss by blindness, glaucoma, diabetic reti-
nopathy, and cataract.26e29 It has also been reported that the
leading causes of visual impairment in Japan were glaucoma
(24.3%), diabetic retinopathy (20.6%), degenerative myopia (12.2%),
age-related macular degeneration (10.9%), and cataract (7.2%).30
Our ﬁnding that ophthalmic disease is one of the major de-
terminants of activity limitation is consistent with the ﬁndings of
these studies.
The prevalence of psychiatric diseases was lower than that of
arthropathia, backache, and ophthalmic diseases. However, ORs of
psychiatric diseases were higher than the ORs of those diseases.
This means that a high proportion of affected individuals have ac-
tivity limitation. In 2010, mental disease was reported as a major
burden of Years Lost due to Disability in the United Kingdom, Iran,
and China.31e33 Also, in Japan, mental disorders were added to the
ﬁve major diseases in 2011.34
Looking at gender differences of PAF in our study, PAFs of
osteoporosis, arthropathia, stiff shoulder, backache, and rheuma-
toid arthritis were higher in females than males. Furthermore,
Table 3
OR and PAF for each disease and injury among both sexes and for males and females separately.
Both sexes Males Females PAF difference (males e females) (%)
OR PAF (%) OR PAF (%) OR PAF (%)
01. Diabetes 2.15 4.99 2.16 6.39 2.13 3.93 2.46
02. Adiposity 3.14 1.11 3.27 1.01 3.08 1.19 0.18
03. Hyperlipemia 1.47 2.44 1.71 2.95 1.34 2.04 0.92
04. Thyroid diseases 2.00 1.03 1.97 0.45 2.01 1.45 1.00
05. Depression and other mental diseases 11.55 5.70 13.17 5.12 10.59 6.11 0.99
06. Dementia 6.38 1.98 6.97 1.48 6.09 2.34 0.85
07. Parkinson's disease 19.27 0.85 13.15 0.75 29.47 0.92 0.17
08. Other nervous diseases 9.37 2.68 12.20 2.77 7.60 2.59 0.18
09. Eye and optical diseases 2.00 6.39 2.49 6.65 1.77 6.08 0.57
10. Ear and aural diseases 2.74 1.96 3.05 2.03 2.55 1.90 0.13
11. Hypertension 1.28 4.38 1.40 5.83 1.19 3.11 2.72
12. Cerebrovascular diseases 5.19 4.27 5.36 6.06 4.87 2.92 3.14
13. Angina pectoris and Myocardial infarction 2.82 3.88 2.95 5.14 2.61 2.90 2.24
14. Other circulatory system diseases 3.24 3.66 3.53 4.28 2.95 3.16 1.11
15. Acute rhinitis/laryngitis 3.45 0.97 4.06 0.95 3.14 0.99 0.04
16. Allergic rhinitis 2.74 2.04 3.16 2.25 2.43 1.86 0.39
17. Asthma 2.98 1.94 2.55 1.65 3.35 2.16 0.50
18. Other respiratory system diseases 4.48 2.42 4.41 3.27 4.63 1.79 1.49
19. Gastric and duodenum diseases 2.14 2.45 1.96 2.42 2.32 2.48 0.06
20. Hepatic and gallbladder disease 3.09 2.44 3.50 3.34 2.66 1.76 1.59
21. Other digestive system diseases 3.03 2.02 3.42 2.21 2.72 1.85 0.36
22. Dental diseases 1.54 2.60 1.63 2.87 1.47 2.37 0.50
23. Atopic dermatitis 2.70 0.83 3.04 1.03 2.39 0.68 0.36
24. Other skin diseases 2.38 2.47 2.12 2.29 2.60 2.59 0.30
25. Gout 1.92 0.76 1.77 1.38 3.68 0.31 1.07
26. Rheumatoid arthritis 5.93 2.62 5.60 1.18 6.09 3.70 2.53
27. Arthropathia 4.82 7.61 5.51 4.88 4.63 9.65 4.76
28. Stiff shoulder 2.40 4.74 2.59 2.95 2.34 6.08 3.13
29. Backache 3.88 13.27 4.15 11.61 3.73 14.47 2.86
30. Osteoporosis 2.76 3.51 3.69 0.60 2.78 5.75 5.16
31. Kidney diseases 5.79 2.75 6.16 3.34 5.41 2.31 1.03
32. Hypertrophy of prostate 2.24 1.91 2.30 4.58 e e e
33. Failure at or after menopause 3.82 0.40 e e 3.75 0.69 e
34. Fracture 12.44 2.67 15.69 2.36 10.25 2.87 0.51
35. Injury or burn other than bone fracture 6.96 1.91 9.60 2.22 5.39 1.66 0.56
36. Anemia and Blood diseases 4.58 1.77 3.63 1.06 4.96 2.28 1.22
37. Malignant neoplasms 4.33 1.68 4.42 1.88 4.22 1.53 0.35
38. Pregnancy and Postpartum 4.03 0.29 e e 3.96 0.51 e
OR, odds ratio; PAF, population attributable fraction.
P values of all ORs were <0.001.
OR and PAF were adjusted for age.
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pertension, showed higher PAF for males than for females.
Osteoporosis, arthropathia, stiff shoulder, backache, and rheu-
matoid arthritis showed a much higher prevalence among females
than males, although these diseases showed higher ORs among
males than females. Hence, these diseases that show high PAF are
considered to be of higher prevalence. Some studies reported that
deﬁciency of estrogen increased the risk of developing knee oste-
oarthritis and osteoporosis,35,36 and that psychological stress
increased the risk of developing lower back pain among females.37
As is the case with orthopedic diseases, the prevalence of ce-
rebrovascular diseases and diabetes for males was greater than for
females. Therefore, the sex difference of PAF for diabetes and stroke
is considered to be due to morbidity.
On the other hand, the prevalence of hypertension was almost
the same for both males (9.70%) and females (10.06%), so the sex
difference in the PAF of hypertension is considered to be caused by
complicating diseases. Hypertension itself may not directly cause
activity limitation, but it is associated with cerebrovascular dis-
eases, cardiovascular diseases, kidney diseases, and other condi-
tions.38 Indeed, past studies in hypertension patients showed that
the morbidities of cerebrovascular diseases and cardiovascular
diseases are higher for males than for females.39e41 These studies
support our ﬁndings.The value of our study is that it investigates for the ﬁrst time the
relationship between each disease/injury and activity limitation,
which is directly used to calculate HLE using nationally represen-
tative data. These results identiﬁed how much each disease and
injury affected activity limitation.
There are some limitations to the present study. First, it is a
cross-sectional study. If we conducted a cohort study to examine
incidence to activity limitation, the results may be different
depending on the follow-up time. Second, we calculated ORs
separately for each disease/injury. Some people, especially the
aged, have multiple diseases, but we did not adjust for other
existing disease. Though some concurrent diseases are con-
founders, other diseases may also be intermediate variables. For
example, hypertension may cause kidney disease and lead to ac-
tivity limitation, but kidney disease may also cause hypertension.
Assessing the causal relationships among all of the diseases and
injuries is a future challenge. Third, the target population of those
who participate in the Comprehensive Survey of Living Conditions
consists of people staying at home and does not include people
staying in hospitals and nursing homes. Therefore, the proportion
of those with activity limitation and the prevalence of each disease/
injury may be different from that in the entire population. How-
ever, HLE in Japan and other countries is also calculated for people
staying at home and living independently.
T. Myojin et al. / Journal of Epidemiology 27 (2017) 75e79 79In conclusion, we calculated ORs and PAFs for the association of
various diseases/injuries with activity limitation. Our results indi-
cate that orthopedic diseases, ophthalmic diseases, and psychiatric
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